Checkpoint Therapeutics (CKPT) SEC Filings

Checkpoint Therapeutics received a Schedule 13G/A filing from Beryl Capital and affiliated entities reporting they do not beneficially own any shares of the company's common stock. The filing shows 0 shares held and 0% of the class and explicitly states the reporting persons disclaim beneficial ownership except for any pecuniary interest.

The filing identifies the reporting parties as an investment adviser and related partnerships, confirms the position is reported as "5 percent or less of a class," and includes certifications that the securities were not acquired to influence control. Signatures from Beryl's COO and David A. Witkin are included.